SCHEMBL3086524

SCHEMBL3086524

Cc1cc(F)ccc1S(=O)(=O)Nc1cncc(-c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 5/20 0.48
PIK3CA P42336 5/20 0.45
ALPL P05186 4/20 0.45
PIK3CB P42338 1/20 0.44
FGFR3 P22607 2/20 0.44
KDR P35968 2/20 0.44
FGFR1 P11362 2/20 0.41
MET P08581 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090038 0.92 PIK3CB (0.54) PRF1PIK3CAALPLPIK3CBFGFR1
SCHEMBL3092923 0.91 FGFR3 (0.48) PRF1PIK3CAALPLPIK3CBFGFR3
SCHEMBL3096942 0.89 FGFR3 (0.46) PIK3CAALPLFGFR3KDRFGFR1
SCHEMBL3088485 0.88 PRF1 (0.45) PRF1PIK3CAALPLPIK3CBFGFR3
SCHEMBL3073351 0.88 PIK3CA (0.54) PRF1PIK3CAALPLPIK3CBFGFR3
SCHEMBL3087020 0.86 FGFR3 (0.48) ALPLPIK3CBFGFR3KDRFGFR1
SCHEMBL3084748 0.86 PIK3CA (0.53) PRF1PIK3CAALPLPIK3CBFGFR3
SCHEMBL3087138 0.86 PRF1 (0.47) PRF1PIK3CAALPLPIK3CBFGFR3
SCHEMBL3087774 0.85 FGFR3 (0.46) ALPLFGFR3KDRFGFR1MET
SCHEMBL3084150 0.84 FGFR3 (0.46) PIK3CAALPLFGFR3KDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
EP-2150255-A1 QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS Smithkline Beecham Corporation (US) 2010-02-10 EP disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
WO-2008141065-A1 QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG PRF1 1252/4885PIK3CA 8/4885ALPL 3010/4885
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG PRF1 1252/4885PIK3CA 8/4885ALPL 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.